Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Yıl: 2023 Cilt: 7 Sayı: 2 Sayfa Aralığı: 120 - 134 Metin Dili: İngilizce DOI: 10.14744/ejmo.2023.44908 İndeks Tarihi: 05-07-2023
Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Öz: Objectives: It remains unclear whether hypofractionated (Hypo) thoracic radiotherapy (TRT) is superior to hyperfrac- tionated or conventionally fractionated (Con) TRT in limited-stage small-cell lung cancer. Methods: PubMed, EMBASE, Web of Science, and the Cochrane Library were searched for eligible studies until April 30, 2023. The outcomes of interest were overall survival (OS), and grade ≥3 esophagitis and pneumonitis, reported as hazard ratios (HRs) or odds ratios (ORs) with their 95% confidence intervals (CIs). Results: A total of 23 studies with 7987 patients were identified. Hypo-TRT showed similar OS compared to Hyper-TRT (HR = 1.22, 95% CI: 0.80-1.86 in randomized controlled trials [RCTs] and HR = 1.12, 95% CI: 0.99-1.28 in retrospective studies) and better OS compared to Con-TRT (HR =0.83, 95% CI: 0.70-0.97). Hyper-TRT achieved longer OS compared to Con-TRT in retrospective studies (HR = 0.91, 95% CI: 0.84-0.99), but not in RCTs (HR = 0.90, 95% CI: 0.80-1.01). There were no significant differences in incidence of grade ≥3 esophagitis or pneumonitis between the three schedules. Conclusion: Hyper-TRT (45 Gy) or Con-TRT (60-70 Gy) remains a standard schedule. Hypo-TRT (40-45 Gy) is likely to be an alternative regimen. Nevertheless, these findings need to be validated in large phase 3 RCTs.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
- 1. Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer 2012;13:115–22.
- 2. Farrell MJ, Yahya JB, Degnin C, Chen Y, Holland JM, Henderson MA, et al. Radiation dose and fractionation for limited-stage small-cell lung cancer: survey of US radiation oncologists on practice patterns. Clin Lung Cancer 2019;20:13–9.
- 3. Glatzer M, Faivre-Finn C, De Ruysscher D, Widder J, Van Houtte P, Troost EGC, et al. Once daily versus twice-daily radiotherapy in the management of limited disease small cell lung can- cer - Decision criteria in routine practise. Radiother Oncol 2020;150:26–29.
- 4. Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radio- therapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265–71.
- 5. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhat- nagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 2017;18:1116–25.
- 6. Bogart JA, Wang X, Masters GA, Gao J, Komaki R, Gaspar LE, et al. Phase 3 comparison of high-dose once-daily (QD) tho- racic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538. American Society of Clinical Oncology Annual Meeting 2021; June 4–6. (abstract 8505).
- 7. Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, et al. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncol 2016;55:591–7.
- 8. Qiu B, Li Q, Liu J, Huang Y, Pang Q, Zhu Z, et al. Moderately hy- pofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: a multicenter, phase II, ran- domized trial. Int J Radiat Oncol Biol Phys 2021;111:424–35.
- 9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Pre- ferred reporting items for systematic reviews and meta-analy- ses: the PRISMA statement. Int J Surg 2010;8:336–41.
- 10. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
- 11. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
- 12. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088– 101.
- 13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.
- 14. Tomita N, Kodaira T, Hida T, Tachibana H, Nakamura T, Naka- hara R, et al. The impact of radiation dose and fractionation on outcomes for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010;76:1121–6.
- 15. Watkins JM, Fortney JA, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, et al. Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concur- rent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. Jpn J Radiol 2010;28:340–8.
- 16. Gazula A, Baldini EH, Chen A, Kozono D. Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer. Lung 2014;192:151–8.
- 17. Winther-Larsen A, Hoffmann L, Moeller DS, Khalil AA, Knap MM. Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy. Acta Oncol 2015;54:1574– 81.
- 18. Han D, Hao S, Tao C, Zhao Q, Wei Y, Song Z, et al. Comparison of once daily radiotherapy to 60 Gy and twice daily radiother- apy to 45 Gy for limited stage small-cell lung cancer. Thorac Cancer. 2015;6:643–8.
- 19. Watkins JM, Russo JK, Andresen N, Rountree CR, Zahra A, Mott SL, et al. Long-term outcome comparison for standard fractionation (≥59 Gy) versus hyperfractionated (≥45 Gy) radiotherapy plus concurrent chemotherapy for limited- stage small-cell lung cancer. Rep Pract Oncol Radiother 2020;25:489–93.
- 20. Tan Y, Yang Q, Wu X, Zhu H. Curative effect of hyperfraction- ated accelerated radiotherapy combined with EP chemother- apy regimen on limited-stage small cell lung cancer. J BUON 2021;26:837–43.
- 21. Shidal C, Osmundson EC, Cui Y, Yoon HS, Bailey CE, Cai Q, et al. The role of thoracic radiation therapy dosing in the treatment of limited-stage small cell lung cancer: a study based on the national cancer database. Adv Radiat Oncol 2022;7:100907.
- 22. Videtic GM, Truong PT, Dar AR, Yu EW, Stitt LW. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer us- ing concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2003;57:709–16.
- 23. Socha J, Guzowska A, Tyc-Szczepaniak D, Wierzchowski M,Sprawka A, Szczesna A, et al. Accelerated hypofractionated thoracic radiotherapy in limited disease small cell lung cancer: comparison with the results of conventionally fractionated ra- diotherapy. J BUON 2015;20:146–57.
- 24. Zhang J, Fan M, Liu D, Zhao KL, Wu KL, Zhao WX, et al. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer. Radiat Oncol 2017;12:51.
- 25. Zayed S, Chen H, Ali E, Rodrigues GB, Warner A, Palma DA, et al. Is there a role for hypofractionated thoracic radiation ther- apy in limited-stage small cell lung cancer? a propensity score matched analysis. Int J Radiat Oncol Biol Phys 2020;108:575– 86.
- 26. Bettington CS, Tripcony L, Bryant G, Hickey B, Pratt G, Fay M. A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same over- all time for limited stage small cell lung cancer. J Med Imaging Radiat Oncol 2013;57:105–12.
- 27. Hu X, Xia B, Bao Y, Xu YJ, Wang J, Ma HL, et al. Timing of thorac- ic radiotherapy is more important than dose intensification in patients with limited-stage small cell lung cancer: a parallel comparison of two prospective studies. Strahlenther Onkol 2020;196:172–81.
- 28. Yan M, Sigurdson S, Greifer N, Kennedy TAC, Toh TS, Lindsay PE, et al. A comparison of hypofractionated and twice-daily thoracic irradiation in limited-stage small-cell lung cancer: an overlap-weighted analysis. Cancers (Basel) 2021;13:2895.
- 29. Graabak G, Grønberg BH, Sandvei MS, Nilssen Y, Halvorsen TO. Thoracic radiotherapy in limited-stage SCLC-a population- based study of patterns of care in norway from 2000 until 2018. JTO Clin Res Rep 2021;3:100270.
- 30. Zhou W, Wang P, Ti X, Yin Y, Huang S, Yang Z, et al. Sequential hypofractionated versus concurrent twice-daily radiotherapy for limited-stage small-cell lung cancer: a propensity score- matched analysis. Cancers (Basel) 2022;14:3920.
- 31. Almahmudi M, Atwal P, Casey S, Canlas R, Hsu F. Pattern of practice and comparison of thoracic radiotherapy for the radi- cal treatment of limited-stage small cell lung cancer. Int J Ra- diat Oncol Biol Phys 2020;3:117–8.
- 32. Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Horn- slien K, Madebo T, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol 2021;22:321–31.
- 33. Yang L, Liu L, Yang Y, Lei Y, Wang T, Wu X, et al. Twice-daily vs higher-dose once-daily thoracic radiotherapy for limited-dis- ease small-cell lung cancer: A PRISMA-compliant meta-analy- sis. Medicine (Baltimore) 2020;99:e20518.
- 34. Wu Q, Xiong Y, Zhang S, Chen X, Yi F, Wei Y, et al. A meta-anal- ysis of the efficacy and toxicity of twice-daily vs. once-daily concurrent chemoradiotherapy for limited-stage small cell lung cancer based on randomized controlled trials. Front On- col 2020;9:1460.
- 35. Zhou J, Guo H, Zhang Y, Liu H, Dou Q. Comparative effective- ness and toxicity of radiotherapy regimens in limited stage small cell lung cancer: A network meta-analysis. Cancer Med. 2022 Apr 25. [Epub ahead of print].
- 36. Viani GA, Gouveia AG, Matsuura FK, Jacinto AA, Moraes FY. Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials. Radiother Oncol 2022;173:41–8.
- 37. Zhao J, Wu L, Hu C, Bi N, Wang L. Radiotherapy fraction in limited-stage small cell lung cancer in the modern era: a sys- tematic review and meta-analysis of 8006 reconstructed indi- vidual patient data. Cancers (Basel) 2022;15:277.
- 38. Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, et al. Phase III comparison of twice-daily split-course irra- diation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999;17:2681– 91.
- 39. Blackstock AW, Bogart JA, Matthews C, Lovato JF, McCoy T, Livengood K, et al. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. Clin Lung Cancer 2005;6:287–92.
| APA | l, r, Chen J, Liu T, Dang J (2023). Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. , 120 - 134. 10.14744/ejmo.2023.44908 |
| Chicago | linshuiyu, renchengbo,Chen Jun,Liu Tingting,Dang Jun Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. (2023): 120 - 134. 10.14744/ejmo.2023.44908 |
| MLA | linshuiyu, renchengbo,Chen Jun,Liu Tingting,Dang Jun Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. , 2023, ss.120 - 134. 10.14744/ejmo.2023.44908 |
| AMA | l, r,Chen J,Liu T,Dang J Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. . 2023; 120 - 134. 10.14744/ejmo.2023.44908 |
| Vancouver | l, r,Chen J,Liu T,Dang J Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. . 2023; 120 - 134. 10.14744/ejmo.2023.44908 |
| IEEE | l, r,Chen J,Liu T,Dang J "Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis." , ss.120 - 134, 2023. 10.14744/ejmo.2023.44908 |
| ISNAD | , linshuiyu vd. "Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis". (2023), 120-134. https://doi.org/10.14744/ejmo.2023.44908 |
| APA | l, r, Chen J, Liu T, Dang J (2023). Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Eurasian Journal of Medicine and Oncology, 7(2), 120 - 134. 10.14744/ejmo.2023.44908 |
| Chicago | linshuiyu, renchengbo,Chen Jun,Liu Tingting,Dang Jun Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Eurasian Journal of Medicine and Oncology 7, no.2 (2023): 120 - 134. 10.14744/ejmo.2023.44908 |
| MLA | linshuiyu, renchengbo,Chen Jun,Liu Tingting,Dang Jun Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Eurasian Journal of Medicine and Oncology, vol.7, no.2, 2023, ss.120 - 134. 10.14744/ejmo.2023.44908 |
| AMA | l, r,Chen J,Liu T,Dang J Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Eurasian Journal of Medicine and Oncology. 2023; 7(2): 120 - 134. 10.14744/ejmo.2023.44908 |
| Vancouver | l, r,Chen J,Liu T,Dang J Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Eurasian Journal of Medicine and Oncology. 2023; 7(2): 120 - 134. 10.14744/ejmo.2023.44908 |
| IEEE | l, r,Chen J,Liu T,Dang J "Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis." Eurasian Journal of Medicine and Oncology, 7, ss.120 - 134, 2023. 10.14744/ejmo.2023.44908 |
| ISNAD | , linshuiyu vd. "Hypofractionated Versus Hyperfractionated Versus Conventionally Fractionated Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis". Eurasian Journal of Medicine and Oncology 7/2 (2023), 120-134. https://doi.org/10.14744/ejmo.2023.44908 |
